Celia M Pombo

Celia M Pombo


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Experimental Cell Research
Verified
Journal Article
Closed access
GHGonzalo Hernández
Gonzalo Hernández
Hind LalHind Lal
Hind Lal
Miguel FidalgoMiguel Fidalgo
Miguel Fidalgo
AGAna Guerrero
Ana Guerrero
JZJuan Zalvide
Juan Zalvide
CPCelia M Pombo
Celia M Pombo

27 September 2017 in Diabetologia
Verified
Journal Article
Closed access
PDF file
CICristina Iglesias
Cristina Iglesias
EFEbel Floridia
Ebel Floridia
MSMiriam Sartages
Miriam Sartages
BPBegoña Porteiro
Begoña Porteiro
MFMaría Fraile
María Fraile
JZJuan Zalvide
Juan Zalvide

18 March 2019 in Endocrinology
Verified
Journal Article
Closed access
PDF file
CPCelia M Pombo
Celia M Pombo
CICristina Iglesias
Cristina Iglesias
MSMiriam Sartages
Miriam Sartages
JZJuan Zalvide
Juan Zalvide
Since the discovery of the MST kinase family of proteins (MST1/STK4, MST2/STK3, MST3/STK24 and SOK1/STK25), much has been done that adds to our knowledge of their structure, regulation and function. In the last few years, a series of articles have unveiled a previous unknown relation of these kinases with metabolic regulation and the homeostasis of metabolic tissues. The aim of this review is to bring together this body of data to have a detailed picture of the current knowledge related with these proteins, metabolism, and some of its associated diseases.

1 March 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
MSMiriam Sartages
Miriam Sartages
MGMar García-Colomer
Mar García-Colomer
CICristina Iglesias
Cristina Iglesias
BHBrian W. Howell
Brian W. Howell
MMManuel Macía
Manuel Macía
JZJuan Zalvide
Juan Zalvide
Background: Cavernous cerebral malformations can arise because of mutations in the CCM1, CCM2, or CCM3 genes, and lack of Cdc42 has also been reported to induce these malformations in mice. However, the role of the CCM3 (cerebral cavernous malformation 3)-associated kinases in cavernoma development is not known, and we, therefore, have investigated their role in the process. Methods: We used a combination of an in vivo approach, using mice genetically modified to be deficient in the CCM3-associated kinases STK24 and STK25 (serine/threonine kinases 24 and 25), and the in vitro model of human endothelial cells in which expression of STK24 and STK25 was inhibited by RNA interference. Results: Mice deficient for both Stk24 and Stk25, but not for either of them individually, developed aggressive vascular lesions with the characteristics of cavernomas at an early age. Stk25 deficiency also gave rise to vascular anomalies in the context of Stk24 heterozygosity. Human endothelial cells deficient for both kinases phenocopied several of the consequences of CCM3 loss, and single STK25 deficiency also induced KLF2 expression, Golgi dispersion, altered distribution of β-catenin, and appearance of stress fibers. Conclusions: The CCM3-associated kinases STK24 and STK25 play a major role in the inhibition of cavernoma development. Download figure Download PowerPoint

17 December 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
MSMiriam Sartages
Miriam Sartages
EFEbel Floridia
Ebel Floridia
MGMar García-Colomer
Mar García-Colomer
CICristina Iglesias
Cristina Iglesias
MMManuel Macia-Cortiñas
Manuel Macia-Cortiñas
JZJuan Zalvide
Juan Zalvide
Cerebral cavernous malformations (CCMs) are vascular malformations that can be the result of the deficiency of one of the CCM genes. Their only present treatment is surgical removal, which is not always possible, and an alternative pharmacological strategy to eliminate them is actively sought. We have studied the effect of the lack of one of the CCM genes, CCM3, in endothelial and non-endothelial cells. By comparing protein expression in control and CCM3-silenced cells, we found that the levels of the Epidermal Growth Factor Receptor (EGFR) are higher in CCM3-deficient cells, which adds to the known upregulation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in these cells. Whereas VEGFR2 is upregulated at the mRNA level, EGFR has a prolonged half-life. Inhibition of EGFR family members in CCM3-deficient cells does not revert the known cellular effects of lack of CCM genes, but it induces significantly more apoptosis in CCM3-deficient cells than in control cells. We propose that the susceptibility to tyrosine kinase inhibitors of CCM3-deficient cells can be harnessed to kill the abnormal cells of these lesions and thus treat CCMs pharmacologically.

11 June 2020
Verified
Book Chapter
Closed access
PDF file
JZJuan Zalvide
Juan Zalvide
CACristina Almengló
Cristina Almengló
SVSara Vázquez
Sara Vázquez
MGMar García-Colomer
Mar García-Colomer
MSMiriam Sartages
Miriam Sartages
CPCelia M Pombo
Celia M Pombo